



Cancer Initiation and Progression: A Comprehensive Review of Carcinogenic Substances, Anti-Cancer Therapies, and Regulatory Frameworks

Aadil Shafi Bhat ^a, Mizna Ahmed ^a, Kashif Abbas ^b,
Mohd Mustafa ^{c*}, Mudassir Alam ^b, Mansour A.S. Salem ^a,
Sidra Islam ^d, Irfan Qadir Tantry ^e, Yogendra Singh ^e,
Muizzah Fatima ^b, Nazura Usmani ^b, Mohd Faraz ^f,
Mohammad Afeef ^g and Safia Habib ^{c*}

^a Department of Chemistry, Faculty of Sciences, Aligarh Muslim University, Aligarh, India.

^b Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India.

^c Department of Biochemistry, J.N. Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, India.

^d Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Clinic, Cleveland, USA.

^e Department of Biochemistry, School of Biological Sciences, University of Kashmir, Srinagar, India.

^f Department of Radiodiagnosis, J.N. Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, India.

^g Department of Biosciences, Natural Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/ajrb/2024/v14i4300>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/118556>

Review Article

Received: 15/04/2024

Accepted: 18/06/2024

Published: 22/06/2024

*Corresponding author: E-mail: mohdmustafagc7251@gmail.com, gc7251@myamu.ac.in, saf_h75@yahoo.co.in, safia.bh@amu.ac.in;

Cite as: Bhat , Aadil Shafi, Mizna Ahmed, Kashif Abbas, Mohd Mustafa, Mudassir Alam, Mansour A.S. Salem, Sidra Islam, Irfan Qadir Tantry, Yogendra Singh, Muizzah Fatima, Nazura Usmani, Mohd Faraz, Mohammad Afeef, and Safia Habib. 2024. "Cancer Initiation and Progression: A Comprehensive Review of Carcinogenic Substances, Anti-Cancer Therapies, and Regulatory Frameworks". *Asian Journal of Research in Biochemistry* 14 (4):111-25. <https://doi.org/10.9734/ajrb/2024/v14i4300>.

ABSTRACT

Cancer is a multifaceted disease influenced by genetic mutations and environmental factors, including exposure to carcinogens. This review presents an in-depth analysis of the mechanisms driving cancer initiation, focusing on the roles of carcinogenic chemicals, anticancer therapies, and chemo-preventive agents. The discussion encompasses a broad spectrum of carcinogens: chemical agents like polycyclic aromatic hydrocarbons, physical agents such as ionizing radiation, biological agents like viruses, and certain therapeutic drugs. The multistep nature of carcinogenesis—comprising initiation, promotion, and progression phases—is detailed, with an emphasis on genetic and epigenetic alterations. Methods for testing carcinogenicity, including in vitro and in vivo studies and epidemiological approaches, are highlighted for their significance in identifying potential carcinogens and understanding their mechanisms. To classify and regulate carcinogenic exposures, the review also looks at the risk management plans and regulatory frameworks used by agencies like the European Chemicals Agency (ECHA), the Environmental Protection Agency (EPA), and the International Agency for Research on Cancer (IARC). Additionally, emerging trends in cancer treatment, such as precision oncology, immunotherapy, and early detection technologies, are explored, alongside ongoing challenges like health disparities and ethical issues. The review emphasizes the necessity of a multidisciplinary approach, involving collaboration among researchers, clinicians, regulatory bodies, and public health organizations, to translate scientific findings into effective cancer prevention, detection, and treatment strategies.

Keywords: Carcinogens; carcinogenesis; chemical carcinogens; cancer risk; environmental factors; targeted therapies; mutagenesis; regulatory oversight.

1. INTRODUCTION

Cancer, a complicated and severe disease spectrum, develops as a result of the complex relationship between genetic alterations and extrinsic influences [1-2]. It is characterized by uncontrolled cellular growth and division, leading to the formation of tumors, which are abnormal tissue masses [3,4,5,6]. These tumors can penetrate and damage nearby tissues and, in more worrying situations, spread via the complex process of metastasis to distant anatomical regions [7-8]. While genetic variations lay the groundwork for cancer development, environmental influences also significantly contribute to this malignancy [9]. Carcinogenic substances and certain drugs have emerged as potent factors in increasing susceptibility to cancer among these ecological elements [10]. These compounds can increase cancer risk by directly damaging DNA or disrupting essential cellular processes [11]. As our understanding of the numerous processes underlying the development of cancer deepens, there is an increasing need to carefully examine the diverse properties of these agents and understand their complex relationship with human health [12].

Cancer is primarily driven by uncontrolled cell growth arising from a sequence of genetic mutations within a cell's DNA [13]. These mutations disrupt the regulation of cell cycle

checkpoints, apoptosis (programmed cell death), and DNA repair mechanisms. Consequently, the affected cells gain a selective advantage for unrestricted proliferation, leading to the formation of abnormal cell populations that eventually form tumors [14,15]. While genetic mutations can occur naturally due to errors in DNA replication, exposure to external factors can significantly accelerate this process [16]. Carcinogenic chemicals and medicinal compounds play a substantial role among these external agents, capable of hastening genetic changes. These agents encompass a broad spectrum of chemicals, ranging from industrial contaminants to medicinal compounds, all of which possess the capability to disrupt the delicate balance of biological systems [17]. Some of these chemicals cause direct DNA damage, resulting in structural changes that differ from the normal genetic code [18]. Others disrupt critical cellular pathways, impairing the cell's ability to respond correctly to environmental signals and maintain genetic integrity. Exposure to such substances triggers a hazardous transformation in cells, creating an environment conducive to the initiation of cancerous processes [19,20].

Cancer initiation is a broad and profound topic of scientific and medical investigation characterized by the complicated relationship of numerous variables. The functions of carcinogenic substances and anti-cancer medications are

pivotal components, with the capacity to either cause the disease's beginning or act as indispensable aids in its management [11-23]. This study seeks to comprehensively investigate the complex mechanisms underlying cancer induction by systematically analyzing the roles of carcinogenic chemicals, anti-cancer treatments, and chemo-preventive medicines [24-27]. A complex issue driven by multiple interrelated variables is the rise in cancer incidence and mortality on a global scale. The concurrent trends of population aging and changes in the prevalence and distribution of key cancer risk factors linked to socioeconomic development are all responsible for this increasing burden. Cancer has become a major cause of death as the world's population ages and grows larger [28]. This is partly because cancer mortality rates are significantly lower globally than those of other diseases like stroke and coronary heart disease [29,30]. The correlation between cancer's prevalence as a determinant of premature mortality and the diverse spectrum of social and economic development levels evident across nations underscores the complex relationship of multifaceted factors contributing to the escalating global impact of cancer on public health [31].

Cell death is a fundamental process in both normal physiology and disease states, being a universal fate for all living organisms. It is often categorized into regulated cell death (RCD) and accidental cell death (ACD). ACD occurs due to unexpected external stimuli or injuries, while RCD is orchestrated by specific signaling pathways involving effector molecules [28]. The concept of RCD was introduced through the understanding of apoptosis, first described by Kerr and colleagues in the 1970s, which highlighted its involvement in various physiological and pathological processes [32]. Subsequent research expanded the understanding of RCD beyond apoptosis, identifying several non-apoptotic forms such as lysosome-dependent cell death, NETotic cell death, cuproptosis, ferroptosis, pyroptosis, entosis, parthanatos, alkaliptosis, oxeiptosis, and parthanatos. Studies on the dysregulation of these RCD pathways are rapidly advancing, particularly about various human disorders, including cancer. Dysregulation of physiological RCD or inadequate control of abnormal cell proliferation is closely linked to an increased risk of developing malignant tumors [33].

The wide array of carcinogens capable of inducing cancer presents a perplexing aspect of

the disease's origin. These include potent tumor promoters like TPA, the subtle yet long-lasting effects of arsenic exposure, and the DNA-damaging properties of alkylating agents [34]. Extensive research has been conducted to understand the mechanisms through which these chemicals initiate and promote cancer [35]. Their diverse impacts on cellular functions and molecular pathways contribute to this complexity, highlighting the complex nature of the disease. Simultaneously, the field of anti-cancer pharmacology offers a range of medications, such as COX-2 inhibitors, histone deacetylase (HDAC) inhibitors, and kinase inhibitors, aimed at halting cancer progression. This review not only emphasizes the therapeutic potential of these medications and the importance of maximizing their clinical utility but also explores the mechanisms by which they inhibit tumor growth and metastasis, while also discussing potential avenues for the development of new cancer-fighting drugs. In conjunction with efforts to combat cancer, increasing research emphasizes the importance of cancer prevention. Chemo-preventive agents such as retinoids, barbitol, genistein, and aspirin, along with the regulation of crucial cellular pathways like TGF, TNF, E2F, and Bcl-2, offer a novel approach to reducing cancer risk by halting the progression of precancerous cells and mitigating the effects of carcinogenic agents, showcasing the potential for targeted cancer prevention [36-41].

2. TYPES OF CARCINOGENS

The term "carcinogens" encompasses a wide range of compounds that can be classified into distinct groups, including chemical carcinogens, physical carcinogens, biological carcinogens, and pharmaceuticals with potential carcinogenic properties [42]. Physical carcinogens include various types of radiation capable of inducing cancer. Exposure to ionizing radiation, such as X-rays and gamma rays, can elevate the risk of cancer by generating reactive oxygen species (ROS) and free radicals in cells (Fig. 1). These highly reactive molecules can cause oxidative damage to cellular macromolecules, including DNA, lipids, and proteins, potentially leading to genetic alterations and mutagenesis [43]. Prolonged exposure to ionizing radiation from sources like medical procedures or the environment can heighten the risk of cancer, particularly in tissues sensitive to radiation [44]. Chemical carcinogens are diverse and present in many environmental sources. Certain substances commonly found in tobacco smoke,

industrial pollutants, and some dietary additives can induce cancer [45]. This occurs when otherwise harmless molecules undergo metabolic activation by enzymes like cytochrome P450s, transforming into highly reactive and cancer-causing metabolites. These metabolites can covalently bind to DNA, forming DNA adducts and causing mutations that can disrupt critical genes involved in cell growth and division [46]. Notable chemical carcinogens include polycyclic aromatic hydrocarbons (PAHs) in cigarette smoke and aflatoxins in certain food products. Biological carcinogens, particularly viruses, contribute to cancer development through the production of viral oncoproteins or by integrating their genetic material into host cell genomes. Viral oncoproteins can interact with and disrupt the function of cellular proteins involved in cell cycle regulation, apoptosis, and DNA repair, promoting uncontrolled cell growth and survival [47]. Integration of viral DNA into the host genome can also lead to the activation of proto-oncogenes or inactivation of tumor suppressor genes, further driving carcinogenesis. Examples of such viruses include the hepatitis B virus (HBV), linked to liver cancer through the actions of viral proteins like HBx, and the human papillomavirus (HPV), associated with cervical cancer due to the expression of oncoproteins like E6 and E7 [48]. Certain bacteria can also contribute to cancer development by inducing chronic inflammation. These bacteria release proinflammatory chemokines and cytokines that promote the recruitment and activation of immune cells, leading to sustained inflammatory responses [49,50]. Chronic inflammation generates reactive oxygen and nitrogen species that can cause DNA damage and genomic instability, creating an environment conducive to cancer formation.

Additionally, some therapeutic medications, including specific chemotherapeutic agents and immunosuppressive compounds, can inadvertently cause carcinogenesis by disrupting processes that regulate the cell cycle and DNA repair. For instance, alkylating agents like cyclophosphamide and topoisomerase inhibitors used in cancer treatment can potentially increase the risk of secondary malignancies due to their genotoxic effects [51,52]. Alkylating agents form covalent adducts with DNA, leading to strand breaks and mutations, while topoisomerase inhibitors interfere with the enzymes responsible for resolving DNA supercoiling during replication and transcription, resulting in DNA damage and chromosomal aberrations [53,54]. These diverse

carcinogenic agents underscore the multifaceted nature of cancer initiation and the importance of stringent regulations and public health measures to minimize exposure to these harmful substances. Furthermore, data from the International Agency for Research on Cancer (IARC) indicates that over 100 agents have been classified as known human carcinogens, with many more classified as probable or possible carcinogens [55].

A wide range of carcinogenic substances, each with unique processes and consequences, are involved in carcinogenesis, the complex process that results in the development of cancer. TPA, a strong tumor promoter, is essential for initiating a number of cellular processes that lead to the development of cancer. Arsenic, a natural element and environmental pollutant, has been linked to several types of cancer and has subtle, long-term effects on cellular DNA integrity [56]. Topoisomerase inhibitors hinder DNA replication and repair processes, leading to the accumulation of genetic mutations. Alkylating chemicals, known for their ability to damage DNA, can both initiate and promote cancer [57]. Various carcinogenic factors highlight the complexity of cancer induction and emphasize how crucial it is to comprehend how each one contributes differently to oncogenesis (Table 1).

In cancer therapy, various pharmacological agents play crucial roles in combating the disease. Chemotherapeutic agents, including alkylating agents and topoisomerase inhibitors, are commonly used in clinical cancer management (Table 2). These agents impede cancer cell proliferation by disrupting DNA replication and repair processes. Radiation therapy, another cornerstone of cancer treatment, employs ionizing radiation to target and eliminate malignant cells while minimizing damage to surrounding normal tissues. Hormonal therapies are particularly effective against hormone-dependent cancers, such as breast and prostate cancers, by counteracting the effects of hormones that promote tumor growth.

3. MECHANISMS OF CARCINOGENESIS

Carcinogenesis, the multistep process by which normal cells transform into cancer cells, is driven by a complex relationship of genetic and epigenetic alterations, coupled with the influence of external factors [73]. This complex process can be broadly categorized into three distinct

phases: initiation, promotion, and progression (Fig. 2).

Initiation Phase: The initiation phase is triggered by exposure to carcinogenic agents capable of inducing genetic damage, particularly within crucial genes involved in cell growth, differentiation, and survival. These carcinogenic agents can be chemical, physical, or biological.

Chemical carcinogens, such as polycyclic aromatic hydrocarbons (PAHs) found in tobacco smoke and certain dietary components, can form DNA adducts or generate reactive oxygen species (ROS), leading to oxidative DNA damage [74]. Physical agents, like ultraviolet (UV) radiation and ionizing radiation, can directly induce DNA lesions, including pyrimidine dimers and double-strand breaks, respectively [75].

Table 1. An overview of carcinogenic compounds, their target tissues, modes of action, and associated substances and agents are given in this summary. It is an invaluable resource for comprehending the mechanisms of carcinogenesis, the effects certain compounds have on particular organs or systems, and other variables that determine their effects

Carcinogenic Chemicals	Target Tissue	Potential Mode of Action	Associated Agent/Substance	Reference
Formaldehyde	Nasal Cavity	Induces DNA damage, promotes nasal cancer	Occupational exposure (e.g., certain industries)	[58]
Benzene	Bone Marrow, Blood	Disrupts hematopoiesis, promotes leukemia	Occupational exposure (e.g., petrochemical industry)	[59]
Arsenic	Skin, Lung, Bladder	Promotes oxidative stress, disrupts DNA repair	Contaminated drinking water, certain industrial exposures	[60]
Vinyl Chloride	Liver, Lungs	Metabolites cause DNA damage and protein dysfunction	Occupational exposure (e.g., plastics manufacturing)	[61]
Chromium (VI)	Lung, Nasal Cavity	Generates ROS, DNA damage	Occupational exposure (e.g., in metalworking)	[62]
Nickel Compounds	Lung, Nasal Cavity	Impair DNA repair, cause oxidative stress	Occupational exposure (e.g., nickel refining)	[63]
1,3-Butadiene	Blood, Lymphatic	Forms DNA adducts, disrupts cell cycle control	Occupational exposure (e.g., rubber production)	[64]
Acrylamide	Nervous System, Liver	Forms DNA adducts, induces mutations in nerve cells	Present in certain foods cooked at high temperatures	[65]
Polycyclic Aromatic Hydrocarbons	Various Tissues	Activate carcinogen-metabolizing enzymes, DNA damage	Found in tobacco smoke, air pollution, and grilled meat	[66]

Table 2. A concise reference for understanding these treatments' therapeutic features and indications by categorizing anti-cancer therapies based on their mechanisms of action and common clinical uses

Drug Class	Mechanism of Action	Common Uses	References
Topoisomerase Inhibitors	Interfere with DNA replication and repair	Various cancers	[67]
Alkylating Agents	Induce DNA damage	Hematological and solid tumors	[68]
Radiation Therapy	Destroys cancer cells via ionizing radiation	Various cancers	[69]
Hormonal Therapies	Block hormone activity	Breast, prostate, and other hormone-sensitive cancers	[70-71]
Targeted Therapies	Precisely target molecular pathways	Specific cancer types based on molecular characteristics	[72]




Fig. 1. Illustration of the complex process of carcinogenesis highlighting the four primary causes of cancer: radiation, chemicals, viruses, and bacteria. Ionizing and non-ionizing radiation both produce free radicals and ROS, which cause DNA damage. Chemical carcinogens create carcinogenic metabolites, which can change oncogenes and promote unchecked cell proliferation while also causing DNA damage and mutations. Viral oncoproteins and oncogenic genetic elements enable viruses to interact with cellular proteins to avoid immune surveillance, cause inflammation, and ultimately cause DNA damage. As a result of bacterial infections, proinflammatory chemokines and cytokines are released, causing long-lasting inflammation and DNA damage brought on by ROS. A crucial stage towards the emergence of cancer, DNA damage, and mutations are the common outcome in each instance. This graphic is a helpful visual tool that explains the complex network of connections that underlies the development of cancer as a result of many etiological variables

Biological agents, such as certain viruses (e.g., human papillomavirus (HPV) and hepatitis B virus (HBV)), can integrate their oncogenic viral DNA into the host genome, disrupting cellular pathways and promoting oncogenic transformation [76]. These genetic insults can result in mutations within critical genes, such as proto-oncogenes and tumor suppressor genes. Proto-oncogenes, including RAS, MYC, and EGFR, can undergo activating mutations or amplifications, leading to their constitutive activation and uncontrolled cell proliferation [77]. Conversely, tumor suppressor genes, like TP53, PTEN, and RB1, which normally function as cellular gatekeepers, can be inactivated or lost, compromising their ability to regulate cell cycle progression, DNA repair, and apoptosis [78].

Promotion Phase: The promotion phase follows the initiation phase and is characterized by the clonal expansion of genetically altered cells that have acquired a selective growth advantage. This phase is often driven by the presence of tumor promoters, such as TPA, which can activate signaling pathways involved in cell

proliferation, survival, and inflammation [79]. During this phase, the genetically initiated cells proliferate at a higher rate compared to their normal counterparts, forming a premalignant lesion or a population of clonal cells. This clonal expansion is facilitated by altered signaling pathways within the cells, often triggered by growth factors, hormones, or inflammatory mediators present in the tumor microenvironment [80]. Key molecular events during the promotion phase include the activation of transcription factors like NF- κ B and AP-1, which regulate the expression of genes involved in cell proliferation, angiogenesis, and inflammation. Additionally, the activation of signaling cascades, such as the MAPK and PI3K/AKT pathways, can contribute to the sustained proliferation and survival of the initiated cells [81-83].

Progression Phase: The progression phase represents the advanced stages of carcinogenesis, during which the premalignant cells acquire additional genetic and epigenetic alterations that confer increased malignancy, invasiveness, and metastatic potential [84].

Mechanisms of Carcinogenesis




Fig. 2. Depicts the basic steps of carcinogenesis, such as initiation, promotion, and progression. Initiation refers to genetic changes caused by carcinogens, whereas promotion refers to enhanced cell division among altered cells, eventually leading to tumor development and progression

One hallmark of this phase is the accumulation of genomic instability, resulting from defects in DNA repair mechanisms or the dysregulation of cell cycle checkpoints. This genomic instability leads to the acquisition of new mutations and chromosomal aberrations, further driving the progression of cancer cells towards a more aggressive phenotype. During this phase, cancer cells may acquire the ability to invade surrounding tissues and metastasize to distant sites within the body. This process involves the dysregulation of various molecular pathways, including cell adhesion, extracellular matrix remodeling, angiogenesis, and epithelial-to-mesenchymal transition (EMT) [85-86]. Key players in the progression phase include matrix metalloproteinases (MMPs), which degrade the extracellular matrix, facilitating cancer cell invasion. Additionally, the activation of EMT-inducing transcription factors, such as SNAIL, SLUG, and TWIST, can promote the loss of cell-cell adhesion and the acquisition of a more invasive and migratory phenotype [87-88]. The tumor microenvironment plays a crucial role in the progression phase, providing cancer cells with growth factors, pro-inflammatory cytokines, and other signals that support their survival, proliferation, and metastatic dissemination [89]. For example, hypoxic conditions within solid tumors can stabilize the transcription factor HIF-1 α , which regulates the expression of genes involved in angiogenesis, glycolysis, and pH regulation, promoting tumor growth and metastasis [90,91]. Throughout the various phases of carcinogenesis, epigenetic mechanisms, such as DNA methylation, histone modifications, and non-coding RNAs, contribute to the dysregulation of gene expression patterns, further driving the malignant transformation of cells [92].

4. CARCINOGENICITY TESTING AND REGULATION

Carcinogenicity testing and regulation are critical components of public health efforts to mitigate the adverse effects of exposure to carcinogenic agents and reduce the global burden of cancer [93]. These efforts involve a multifaceted approach, encompassing laboratory-based testing, epidemiological studies, risk assessment, and the implementation of regulatory frameworks.

Carcinogenicity Testing: Carcinogenicity testing aims to identify substances or agents that can potentially cause cancer and elucidate the

underlying mechanisms of carcinogenesis. These tests are typically conducted using in vitro and in vivo models and involve evaluating various endpoints, including genotoxicity, mutagenicity, and the induction of tumors [94]. In vitro tests, such as the Ames test and the micronucleus assay, are used to assess the genotoxic potential of substances by evaluating their ability to induce DNA damage or chromosomal aberrations in bacterial or mammalian cell cultures. These tests can provide valuable insights into the potential mechanisms of carcinogenesis, such as the formation of DNA adducts or the induction of oxidative stress [95]. In vivo tests, including rodent bioassays and transgenic animal models, are crucial for evaluating the carcinogenic potential of substances in living organisms. These tests involve exposing animals to the test substance over an extended period and monitoring for the development of tumors or other cancer-related endpoints [96]. Histopathological examination and molecular analysis of tumor samples can provide valuable information about the mechanisms of carcinogenesis and the specific target organs or tissues affected. Epidemiological studies, which investigate the relationship between exposure to potential carcinogens and cancer incidence in human populations, play a crucial role in carcinogenicity assessment [97].

Regulation and Risk Management: Regulatory agencies, such as the International Agency for Research on Cancer (IARC), the United States Environmental Protection Agency (EPA), and the European Chemicals Agency (ECHA), play a vital role in evaluating the carcinogenic potential of substances and implementing appropriate risk management strategies. These agencies rely on a weight-of-evidence approach, combining data from carcinogenicity testing, epidemiological studies, and mechanistic investigations to classify substances based on their carcinogenic potential. Substances are typically categorized as carcinogenic, probably carcinogenic, possibly carcinogenic, or non-carcinogenic, based on the strength of the evidence. When a substance is identified as a potential carcinogen, regulatory agencies can adopt a variety of risk management strategies to reduce exposure and safeguard public health. These strategies may encompass the establishment of permissible exposure limits for occupational settings or environmental releases, which are based on risk assessments and dose-response analyses. They may also require appropriate labelling and hazard

communication for products containing carcinogenic substances to inform consumers and workers about potential risks [98-101]. In certain cases, particularly where safer alternatives are available, restrictions or outright bans may be imposed on the production, use, or importation of specific carcinogenic substances. The implementation of stringent emission controls and monitoring programs for industrial processes that involve the use or release of carcinogenic substances is another key strategy. Additionally, the promotion of public awareness campaigns and educational programs can play a crucial role in informing the general population about potential exposure sources and strategies for risk mitigation. Regulatory frameworks and risk management strategies are continuously evolving as new scientific evidence emerges and understanding of carcinogenic mechanisms deepens. This iterative process involves collaboration among researchers, regulatory agencies, industry stakeholders, and public health organizations to ensure the effective identification, assessment, and control of carcinogenic risks [102-104]. It is crucial to note that carcinogenicity testing and regulation extend beyond chemicals and substances, encompassing a wide range of potential carcinogens, including physical agents (e.g., ionizing radiation, ultraviolet radiation), biological agents (e.g., certain viruses, bacteria), and lifestyle factors (e.g., tobacco use, dietary habits). A comprehensive approach that addresses all potential sources of carcinogenic exposure is essential for effective cancer prevention and public health protection [105-106].

5. EMERGING TRENDS AND CHALLENGES

Emerging trends and challenges in cancer care reflect the evolving landscape of cancer treatment and research. Precision oncology has emerged as a transformative approach, using tumor molecular profiling to tailor therapies to individual genetic and molecular characteristics, thereby enhancing efficacy while minimizing side effects [107]. Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight cancer, with immune checkpoint inhibitors, CAR-T cell therapy, and therapeutic vaccinations showing promising outcomes. Advances in early cancer detection, facilitated by technologies like liquid biopsies, AI-driven image analysis, and novel biomarkers, have shifted focus towards early interventions,

potentially increasing survival rates [108]. Moreover, cancer care is evolving towards more holistic, patient-centered strategies, integrating psychosocial support, mental health services, and survivor care into treatment programs. Public health initiatives are promoting cancer prevention through lifestyle modifications, including smoking cessation, dietary improvements, increased physical activity, and vaccination against cancer-causing viruses. However, significant challenges persist in the realm of cancer care [109]. Identifying and regulating environmental carcinogens remains a complex task, necessitating further research and stricter regulations to mitigate exposure risks. Immunotherapy, while promising, presents difficulties such as immune-related side effects and resistance mechanisms, underscoring the need for optimization to maximize safety and efficacy [110]. Health disparities in cancer care persist, with disadvantaged communities facing higher incidence rates, delayed diagnosis, and limited access to advanced therapies, highlighting the importance of tailored treatments and improved healthcare access. Ethical considerations regarding data privacy and patient autonomy in cancer research require ongoing attention to balance scientific progress with ethical standards [111]. Moreover, patient empowerment through information sharing and shared decision-making is essential for enhancing treatment outcomes and ensuring active patient involvement in their care.

6. CONCLUSION

The complexities surrounding cancer initiation, progression, and treatment underscore the multifaceted nature of this disease. Understanding the diverse mechanisms by which carcinogenic agents contribute to genetic and epigenetic alterations is crucial for developing effective preventive and therapeutic strategies. Stringent regulatory frameworks and public health initiatives are vital to mitigate exposure risks from chemical, physical, and biological carcinogens. While advances in precision oncology, immunotherapy, and early detection techniques have revolutionized cancer care, significant challenges persist. Identifying and regulating environmental carcinogens remain complex tasks, necessitating further research and stricter regulations. Optimizing immunotherapies to maximize efficacy while minimizing side effects is an ongoing endeavor. Addressing health disparities and improving access to advanced therapies for disadvantaged

communities is imperative. Moreover, ethical considerations regarding data privacy, patient autonomy, and shared decision-making warrant continuous attention to balance scientific progress with ethical standards. Integrating psychosocial support, mental health services, and survivor care into treatment programs promotes a holistic, patient-centered approach to cancer care. Ultimately, tackling the complexities of cancer initiation, progression, and treatment requires a comprehensive, multidisciplinary approach. Collaboration among researchers, clinicians, regulatory bodies, and public health organizations is essential to translate scientific insights into evidence-based strategies for prevention, early detection, and effective treatment. By addressing emerging trends and challenges, we can pave the way for a future where cancer is not only better understood but also more effectively managed and prevented, ultimately reducing its global burden.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models and text-to-image generators have been used during writing or editing of manuscripts.

FUNDING

This work is part of research supported by the Indian Council of Medical Research, New Delhi [Sanction Letter No. 45/24/2022-/BIO/BMS] to Mohd Mustafa and University Grants Commission [Project ID No. 2021-13007] to Safia Habib.

COMPETING INTERESTS

The authors declare they have no discernible competing financial interests or personal connections that could influence this work.

REFERENCES

1. Haas OA. Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework. *Front Immunol.* 2019;9:3136.
2. Carbone M, Arron ST, Beutler B, Bononi A, Cavenee W, Cleaver JE, Croce CM, D'Andrea A, Foulkes WD, Gaudino G, Groden JL, Henske EP, Hickson ID, Hwang PM, Kolodner RD, Mak TW, Malkin D, Monnat RJ Jr, Novelli F, Pass HI, Petrini JH, Schmidt LS, Yang H. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. *Nat Rev Cancer.* 2020;20(9):533-549.
3. Suarez-Torres JD, Alzate JP, Orjuela-Ramirez ME. The NTP Report on Carcinogens: A valuable resource for public health, a challenge for regulatory science. *J Appl Toxicol.* 2020;40(1):169-175.
4. Das P, Kemiseti D, Jahan FI, Spruha SE, Raka SC. A Comprehensive Review on the Formation of Carcinogens from Food Products with Respect to Different Cooking Methods. *J. Pharm. Res. Int.* [Internet]. 2021;33(41B):360-72. Available: <https://journaljpri.com/index.php/JPRI/article/view/3173>
5. Whiteside M, Herndon JM. Coal Fly Ash Aerosol: Risk Factor for Lung Cancer. *J. Adv. Med. Med. Res.* [Internet]. 2018;25(4):1-10. Available: <https://journaljammr.com/index.php/JAMMR/article/view/2828>
6. Calabrese EJ, Priest ND, Kozumbo WJ. Thresholds for carcinogens. *Chemico-Biological Interactions.* 2021;341:109464.
7. Migliore L, Coppedè F. Genetic and environmental factors in cancer and neurodegenerative diseases. *Mutat Res.* 2002;512(2-3):135-53.
8. Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. *Journal of Cancer Research and Practice.* 2017;4(4):127-9.
9. Talseth-Palmer B, Scott R. Genetic Variation and its Role in Malignancy. *International journal of biomedical science : IJBS.* 2011;7:158-71.
10. Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: Properties, sources, targets, and their implication in various diseases. *Indian J Clin Biochem.* 2015;30(1):11-26.
11. Barnes JL, Zubair M, John K, Poirier MC, Martin FL. Carcinogens and DNA damage. *Biochem Soc Trans.* 2018;46(5):1213-1224.
12. Shams M, Nezhad N, dehghan A, Alidadi H, Paydar M, Mohammadi A, et al. Heavy metals exposure, carcinogenic and non-carcinogenic human health risks assessment of groundwater around mines in Joghatai, Iran. *International Journal of Environmental Analytical Chemistry.* 2020;102:1-16

13. Khan Z, Bisen PS. Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. *Biochim Biophys Acta*. 2013;1836(1):123-45.
14. Gebel J, Tuppi M, Sanger N, Schumacher B, Dotsch V. DNA Damaged Induced Cell Death in Oocytes. *Molecules*. 2020;25(23):5714.
15. Surova O, Zhivotovsky B. Various modes of cell death induced by DNA damage. *Oncogene*. 2013 Aug 15;32(33):3789-97. DOI: 10.1038/onc.2012.556. Epub 2012 Dec 3. PMID: 23208502.
16. Aguado J, Gomez-Inclan C, Leeson HC, Lavin MF, Shiloh Y, Wolvetang EJ. The hallmarks of aging in Ataxia-Telangiectasia. *Ageing Research Reviews*. 2022;79:101653.
17. Dutta S, Mahalanobish S, Saha S, Ghosh S, Sil PC. Natural products: An upcoming therapeutic approach to cancer. *Food Chem Toxicol*. 2019;128:240-255.
18. Nilsson R, Liu N-A. Nuclear DNA damages generated by reactive oxygen molecules (ROS) under oxidative stress and their relevance to human cancers, including ionizing radiation-induced neoplasia part I: Physical, chemical and molecular biology aspects. *Radiation Medicine and Protection*. 2020;1(3):140-52.
19. Yuan M, Zhang G, Bai W, Han X, Li C, Bian S. The Role of Bioactive Compounds in Natural Products Extracted from Plants in Cancer Treatment and Their Mechanisms Related to Anticancer Effects. *Oxid Med Cell Longev*. 2022;2022:1429869.
20. Pathak MP, Pathak K, Saikia R, Gogoi U, Ahmad MZ, Patowary P, Das A. Immunomodulatory effect of mushrooms and their bioactive compounds in cancer: A comprehensive review. *Biomed Pharmacother*. 2022;149:112901.
21. Kim KW, Roh JK, Wee HJ, Kim C. *Cancer Drug Discovery: Science and History*: Springer Netherlands; 2016.
22. Bijauliya R, Alok DS, Singh M, Mishra DSB. A comprehensive review on cancer and anticancer herbal drugs. *International Journal of Pharmaceutical Sciences and Research*. 2017;8:2740-61.
23. Bhandaria M, Ravipati A, Reddy N, Koyyalamudi S. Traditional Ayurvedic medicines: Pathway to develop anti-cancer drugs. *Journal of Molecular Pharmaceutics & Organic Process Research*. 2015;03.
24. Racz B, Spengler G. Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases. *Antibiotics (Basel)*. 2023;12(1):137.
25. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast Cancer Statistics, 2022. *CA Cancer J Clin*. 2022;72(6):524-541.
26. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther*. 2021;6(1):263.
27. Testa U, Castelli G, Pelosi E. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. *Medicines (Basel)*. 2019;6(3):82.
28. Santagostino SF, Assenmacher CA, Tarrant JC, Adedeji AO, Radaelli E. Mechanisms of Regulated Cell Death: Current Perspectives. *Vet Pathol*. 2021;58(4):596-623.
29. Zaorsky NG, Zhang Y, Tchelebi LT, Mackley HB, Chinchilli VM, Zacharia BE. Stroke among cancer patients. *Nat Commun*. 2019;10(1):5172.
30. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. *Eur J Heart Fail*. 2019;21(12):1515-1525.
31. Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of Gene-Environment Interactions on Cancer Development. *Int J Environ Res Public Health*. 2020 Nov 3;17(21):8089. DOI:10.3390/ijerph17218089. PMID: 33153024; PMCID: PMC7662361.
32. Deng F, Zheng X, Sharma I, Dai Y, Wang Y, Kanwar YS. Regulated cell death in cisplatin-induced AKI: relevance of myo-inositol metabolism. *Am J Physiol Renal Physiol*. 2021;320(4):F578-F595.
33. Yang HC, Wu YH, Yen WC, Liu HY, Hwang TL, Stern A, Chiu DT. The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. *Cells*. 2019;8(9):1055.
34. Abstracts of the Environmental Mutagen Society 43rd Annual Meeting. September 8-12, 2012. Bellevue, Washington, USA. *Environ Mol Mutagen*. 2012;53 Suppl 1:S13-70.
35. Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. *DNA Repair (Amst)*. 2019;83:102673.

36. Schultze E, Collares T, Lucas CG, Seixas FK. Synergistic and additive effects of ATRA in combination with different anti-tumor compounds. *Chem Biol Interact.* 2018;285:69-75.
37. Xiong M, Hu W, Tan Y, Yu H, Zhang Q, Zhao C, Yi Y, Wang Y, Wu Y, Wu M. Transcription Factor E2F1 Knockout Promotes Mice White Adipose Tissue Browning Through Autophagy Inhibition. *Front Physiol.* 2021;12:748040.
38. Trosko JE, Chang CC. Factors to consider in the use of stem cells for pharmaceutical drug development and for chemical safety assessment. *Toxicology.* 2010;270(1):18-34.
39. Bartsch H, Frank N, Gerhäuser C, Owen RW, Berger MR. International Meeting on Cancer Chemoprevention: molecular basis, mechanisms and trials. *Eur J Cancer Prev.* 1997 Feb;6(1):80-92.
40. Charidemou E, Koufaris C, Louca M, Kirmizis A, Rubio-Tomás T. Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview. *Clin Transl Oncol.* 2023;25(6):1594-1605.
41. De Flora S, Ferguson L. Overview of mechanisms of cancer chemopreventive agents. *Mutation research.* 2006;591:8-15.
42. Smith MT, Guyton KZ, Gibbons CF, Fritz JM, Portier CJ, Rusyn I, DeMarini DM, Caldwell JC, Kavlock RJ, Lambert PF, Hecht SS, Bucher JR, Stewart BW, Baan RA, Coglianò VJ, Straif K. Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis. *Environ Health Perspect.* 2016;124(6):713-21.
43. Reisz JA, Bansal N, Qian J, Zhao W, Furdui CM. Effects of ionizing radiation on biological molecules--mechanisms of damage and emerging methods of detection. *Antioxid Redox Signal.* 2014;21(2):260-92.
44. Borrego-Soto G, Ortiz-López R, Rojas-Martínez A. Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer. *Genet Mol Biol.* 2015;38(4):420-32.
45. Parsa N. Environmental factors inducing human cancers. *Iran J Public Health.* 2012;41(11):1-9.
46. Reed L, Arlt VM, Phillips DH. The role of cytochrome P450 enzymes in carcinogen activation and detoxication: an in vivo-in vitro paradox. *Carcinogenesis.* 2018;39(7):851-859.
47. Katerji M, Duerksen-Hughes PJ. DNA damage in cancer development: special implications in viral oncogenesis. *Am J Cancer Res.* 2021;11(8):3956-3979.
48. Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P. Viral carcinogenesis: factors inducing DNA damage and virus integration. *Cancers (Basel).* 2014;6(4):2155-86.
49. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. *Ann Afr Med.* 2019;18(3):121-126.
50. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther.* 2021;6(1):263.
51. Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. *Front Genet.* 2015;6:157.
52. Weber GF. DNA Damaging Drugs. *Molecular Therapies of Cancer.* 2014:9-112.
53. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C. Repair of topoisomerase I-mediated DNA damage. *Prog Nucleic Acid Res Mol Biol.* 2006;81:179-229.
54. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. *J Nucleic Acids.* 2010;2010:543531.
55. Turner MC, Coglianò V, Guyton K, Madia F, Straif K, Ward EM, Schubauer-Berigan MK. Research Recommendations for Selected IARC-Classified Agents: Impact and lessons learned. *Environ Health Perspect.* 2023;131(10):105001.
56. Speer RM, Zhou X, Volk LB, Liu KJ, Hudson LG. Arsenic and cancer: Evidence and mechanisms. *Adv Pharmacol.* 2023;96:151-202.
57. Alhmoud JF, Woolley JF, Al Moustafa AE, Malki MI. DNA Damage/Repair Management in Cancers. *Cancers (Basel).* 2020;12(4):1050.
58. Nishikawa A, Nagano K, Kojima H, Ogawa K. A comprehensive review of mechanistic insights into formaldehyde-induced nasal cavity carcinogenicity. *Regul Toxicol Pharmacol.* 2021;123:104937.

59. Spatari G, Allegra A, Carrieri M, Pioggia G, Gangemi S. Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression. *Cancers (Basel)*. 2021; 13(10):2392.
60. Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, Rhodes CJ, Valko M. Arsenic: toxicity, oxidative stress and human disease. *J Appl Toxicol*. 2011; 31(2):95-107.
61. Kielhorn J, Melber C, Wahnschaffe U, Aitio A, Mangelsdorf I. Vinyl chloride: still a cause for concern. *Environ Health Perspect*. 2000;108(7):579-88.
62. Mishra S, Bharagava RN. Toxic and genotoxic effects of hexavalent chromium in environment and its bioremediation strategies. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev*. 2016;34(1):1-32.
63. Kanwar P, Kumar M, Srivastava S. Investigation of phytoextraction and tolerance capacity of *Calotropis procera* for the detoxification of hexavalent chromium, nickel, and lead. *Environmental Technology & Innovation*. 2023;32:103238.
64. Schmiederer M, Knutson E, Muganda P, Albrecht T. Acute exposure of human lung cells to 1,3-butadiene diepoxide results in G1 and G2 cell cycle arrest. *Environ Mol Mutagen*. 2005;45(4):354-64.
65. Exon JH. A review of the toxicology of acrylamide. *J Toxicol Environ Health B Crit Rev*. 2006;9(5):397-412.
66. Ifegwu OC, Anyakora C. Polycyclic Aromatic Hydrocarbons: Part I. Exposure. *Adv Clin Chem*. 2015;72:277-304.
67. Xu Y, Her C. Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. *Biomolecules*. 2015;5(3):1652-70.
68. Ralhan R, Kaur J. Alkylating agents and cancer therapy. *Expert Opin Ther Pat*. 2007;17:1061-75.
69. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. *Front Mol Biosci*. 2014;1:24.
70. Liu WJ, Zhao G, Zhang CY, Yang CQ, Zeng XB, Li J, Zhu K, Zhao SQ, Lu HM, Yin DC, Lin SX. Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. *J Cell Biochem*. 2020;121(4):2756-2769.
71. Bayala B, Zoure AA, Baron S, de Joussineau C, Simpore J, Lobaccaro JA. Pharmacological Modulation of Steroid Activity in Hormone-Dependent Breast and Prostate Cancers: Effect of Some Plant Extract Derivatives. *Int J Mol Sci*. 2020; 21(10):3690.
72. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. *Eur J Pharmacol*. 2018; 834:188-196.
73. Ciriello G, Magnani L, Aitken SJ, Akkari L, Behjati S, Hanahan D, Landau DA, Lopez-Bigas N, Lupiáñez DG, Marine JC, Martin-Villalba A, Natoli G, Obenauf AC, Oricchio E, Scaffidi P, Sottoriva A, Swarbrick A, Tonon G, Vanharanta S, Zuber J. Cancer Evolution: A Multifaceted Affair. *Cancer Discov*. 2024;14(1): 36-48.
74. Barnes JL, Zubair M, John K, Poirier MC, Martin FL. Carcinogens and DNA damage. *Biochem Soc Trans*. 2018;46(5):1213-1224.
75. Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP. Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. *J Nucleic Acids*. 2010;2010 :592980.
76. Mui UN, Haley CT, Tying SK. Viral Oncology: Molecular Biology and Pathogenesis. *J Clin Med*. 2017;6(12):111.
77. Chowdhary S, Deka R, Panda K, Kumar R, Solomon AD, Das J, Kanoujiya S, Gupta AK, Sinha S, Ruokolainen J, Kesari KK, Gupta PK. Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities. *Mol Pharm*. 2023;20(8):3698-3740.
78. Datta N, Chakraborty S, Basu M, Ghosh MK. Tumor Suppressors Having Oncogenic Functions: The Double Agents. *Cells*. 2020;10(1):46.
79. Kolb TM, Davis MA. The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) provokes a prolonged morphologic response and ERK activation in Tsc2-null renal tumor cells. *Toxicol Sci*. 2004;81(1):233-42.
80. Polverini PJ, Nör F, Nör JE. Crosstalk between cancer stem cells and the tumor microenvironment drives progression of premalignant oral epithelium. *Front Oral Health*. 2023;3:1095842.
81. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. *Expert Opin Ther Targets*. 2010;14(1):45-55.
82. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB,

- Abbruzzese JL, Chiao PJ. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. *Mol Cell Biol.* 2004;24(17):7806-19.
83. Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. *Signal Transduct Target Ther.* 2020;5(1):209.
84. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. *Science.* 2020;368(6487):eaaw5473.
85. Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano K, Azmi AS, Bhakta D, Bilsland A, Boosani CS, Chen S, Ciriolo MR, Fujii H, Guha G, Halicka D, Helferich WG, Keith WN, Mohammed SI, Niccolai E, Yang X, Honoki K, Parslow VR, Prakash S, Rezazadeh S, Shackelford RE, Sidransky D, Tran PT, Yang ES, Maxwell CA. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. *Semin Cancer Biol.* 2015;35 Suppl(Suppl):S5-S24.
86. Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. *Signal Transduct Target Ther.* 2021;6(1):254.
87. Mustafa S, Koran S, AlOmair L. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review. *Front Mol Biosci.* 2022;9:896099.
88. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. *J Mammary Gland Biol Neoplasia.* 2010;15(2):201-12.
89. Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. *Cancers (Basel).* 2021;13(9):2053.
90. Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. *Yale J Biol Med.* 2007;80(2):51-60.
91. Zhang M, Zhang Y, Ding Y, Huang J, Yao J, Xie Z, Lv Y, Zuo J. Regulating the Expression of HIF-1α or lncRNA: Potential Directions for Cancer Therapy. *Cells.* 2022;11(18):2811.
92. Kanwal R, Gupta S. Epigenetic modifications in cancer. *Clin Genet.* 2012;81(4):303-11.
93. Madia F, Worth A, Whelan M, Corvi R. Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment. *Environ Int.* 2019;128:417-429.
94. Barguilla I, Maguer-Satta V, Guyot B, Pastor S, Marcos R, Hernández A. In Vitro Approaches to Determine the Potential Carcinogenic Risk of Environmental Pollutants. *Int J Mol Sci.* 2023;24(9):7851.
95. Pinter E, Rainer B, Czerny T, Riegel E, Schilter B, Marin-Kuan M, Tacker M. Evaluation of the Suitability of Mammalian In Vitro Assays to Assess the Genotoxic Potential of Food Contact Materials. *Foods.* 2020;9(2):237.
96. Felter SP, Bhat VS, Botham PA, Bussard DA, Casey W, Hayes AW, Hilton GM, Magurany KA, Sauer UG, Ohanian EV. Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop. *Crit Rev Toxicol.* 2021;51(8):653-694.
97. Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 5, Cancer. Available:<https://www.ncbi.nlm.nih.gov/books/NBK53010/>
98. National Toxicology Program. 15th Report on Carcinogens [Internet]. Research Triangle Park (NC): National Toxicology Program; 2021 Dec 21. Introduction. Available:<https://www.ncbi.nlm.nih.gov/books/NBK590915/>
99. Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC. Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society. *Regul Toxicol Pharmacol.* 2016;82:158-166.

100. Available:<https://echa.europa.eu/registration-dossier/-/registered-dossier/11204/7/8>
101. Available:<https://iacr.who.int/>
102. Available:<https://www.epa.gov/environmental-topics/epa-efforts-reduce-exposure-carcinogens-and-prevent-cancer>
103. Slavik CE, Kalenge S, Demers PA. Industry and geographic patterns of use and emission of carcinogens in Ontario, Canada, 2011-2015. *Can J Public Health*. 2018 Dec;109(5-6):769-778.
104. Espina C, Porta M, Schüz J, Aguado IH, Percival RV, Dora C, Slevin T, Guzman JR, Meredith T, Landrigan PJ, Neira M. Environmental and occupational interventions for primary prevention of cancer: a cross-sectorial policy framework. *Environ Health Perspect*. 2013;121(4):420-6.
105. Kumari S, Sharma S, Advani D, Khosla A, Kumar P, Ambasta RK. Unboxing the molecular modalities of mutagens in cancer. *Environ Sci Pollut Res Int*. 2022;29(41):62111-62159.
106. Birkett N, Al-Zoughool M, Bird M, Baan RA, Zielinski J, Krewski D. Overview of biological mechanisms of human carcinogens. *J Toxicol Environ Health B Crit Rev*. 2019;22(7-8):288-359.
107. Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. *Technology (Singap World Sci)*. 2018;6(3-4):79-100.
108. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. *J Clin Invest*. 2015;125(9):3335-7.
109. Recklitis CJ, Syrjala KL. Provision of integrated psychosocial services for cancer survivors post-treatment. *Lancet Oncol*. 2017;18(1):e39-e50.
110. Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraiyani T, Vasanthan M, Viktor P, Lakshmaiyi N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. *Mol Cancer*. 2023;22(1):169.
111. Kale S, Hirani S, Vardhan S, Mishra A, Ghode DB, Prasad R, Wanjari M. Addressing Cancer Disparities Through Community Engagement: Lessons and Best Practices. *Cureus*. 2023;15(8):e43445.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/118556>